v3.20.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Revenue
General and administrative expense 2,625 1,693
Research and development expense 2,628 1,451
Total operating expenses 5,253 3,144
Loss from operations (5,253) (3,144)
Other income (expense)    
Interest expense (52)
Change in fair value - Senior Secured Convertible Notes (8,008) (559)
Offering costs - issue of Senior Secured Convertible Note - Series B (410)
Debt extinguishments loss - Senior Secured Convertible Notes (1,188) (1)
Other income (expense), net (9,658) (560)
Loss before provision for income tax (14,911) (3,704)
Provision for income taxes
Net loss - before noncontrolling interest (14,911) (3,704)
Net loss attributable to noncontrolling interest 436 169
Net loss - attributable to PAVmed Inc. (14,475) (3,535)
Less: Series B Convertible Preferred Stock dividends earned (70) (65)
Net loss attributable to PAVmed Inc. common stockholders $ (14,545) $ (3,600)
Net loss per share - attributable to PAVmed Inc. - basic and diluted $ (0.33) $ (0.13)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted $ (0.33) $ (0.13)
Weighted average common shares outstanding - basic and diluted 43,500 27,149

Source